Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F0002-ADC in CD30+ Hematologic Malignancies
NCT03894150Phase 1Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Jul 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD30-DM1 in CD30-positive lymphoid malignancy, classic Hodgkin lymphoma (cHL), anaplastic large cell lymphoma (ALCL) and 1 more, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoint: Maximum Tolerable Dose at 21 days. Started Apr 2019; status: completed.
02
Drugs
CD30-DM1
03
Conditions
CD30-positive lymphoid malignancyclassic Hodgkin lymphoma (cHL)anaplastic large cell lymphoma (ALCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03894150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894150.